Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 6/20 | 0.49 |
| ▸ | CRHR1 | P34998 | 12/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593564 | 0.90 | CYP1A2 (0.48) | NPY1RCRHR1GRM8CYP1A2GRM7 | |
| SCHEMBL1594404 | 0.88 | NPY1R (0.49) | NPY1RCRHR1GRM8CYP1A2GRM7 | |
| SCHEMBL1593501 | 0.86 | NPY1R (0.47) | NPY1RCRHR1GRM8CYP1A2GRM7 | |
| SCHEMBL1594245 | 0.86 | NPY1R (0.47) | NPY1RCRHR1GRM8CYP1A2GRM7 | |
| SCHEMBL1593495 | 0.85 | NPY1R (0.52) | NPY1RCRHR1GRM8CYP1A2GRM7 | |
| SCHEMBL1594081 | 0.83 | NPY1R (0.45) | NPY1RCRHR1GRM8CYP1A2GRM7 | |
| SCHEMBL1593270 | 0.83 | NPY1R (0.56) | NPY1RCRHR1GRM8CYP1A2GRM7 | |
| SCHEMBL7043850 | 0.83 | ALDH1A1 (0.45) | NPY1RCRHR1GRM8CYP1A2GRM7 | |
| SCHEMBL1593938 | 0.82 | NPY1R (0.46) | NPY1RCRHR1GRM8CYP1A2GRM7 | |
| SCHEMBL1593385 | 0.82 | NPY1R (0.49) | NPY1RCRHR1GRM8CYP1A2GRM7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176630-A1 | adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176630-A1 | adminsteration of Peptide YY or an agonist to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism | NPY4R, NPY2R, NPY1R | NPY1R 3/4885CRHR1 40/4885GRM8 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.